Abstracts tagged "steroids and treatment"

Abstract Number: 477 • 2018 ACR/ARHP Annual Meeting
Early Treatment with Intravenous Pulse Methylprednisolone or Methotrexate Is Associated with Decreased Medication Requirements at 12 and 24 Months in Patients with Juvenile Dermatomyositis: A Propensity Score Analysis
Takayuki Kishi^1,2, Jesse Wilkerson³, Marjo Smith³, Nastaran Bayat¹, Michael Henrickson⁴, Bianca Lang⁵, Murray Passo⁶, Frederick W. Miller¹, Michael Ward⁷ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, ³Social & Scientific Systems, Inc., Durham, NC, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, ⁶Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Daily oral prednisone has been the main therapy in juvenile dermatomyositis (JDM), and combination therapy with methotrexate (MTX) introduced soon after diagnosis has been…
Abstract Number: 1112 • 2017 ACR/ARHP Annual Meeting
Efficacy of High Dose Versus Moderate Dose Prednisone in the Treatment of Acute Gout
Rochella A. Ostrowski¹, Elizabeth Araujo², Richard Hariman³ and Elaine Adams⁴, ¹Division of Rheumatology, Loyola University Medical Center, Maywood, IL, ²Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Rheumatology, Edward Hines Jr Hospital, Veterans Administration, Hines, IL
Background/Purpose: Despite the use of corticosteroids in acute gout, there exist wide variations in treatment doses and duration. No studies have evaluated the ideal dose…
Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Rajaie Namas¹, Corey Powell² and J. Michelle Kahlenberg³, ¹Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ²Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…
Abstract Number: 385 • 2012 ACR/ARHP Annual Meeting
The Wide Variation in Corticosteroid Use in Early Rheumatoid Arthritis – There Is Need for Guidelines
A. Bharadwaj¹ and Carol Alves², ¹Rheumatology, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom, ²Research & Development, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which causes significant pain and swelling in the joints. The early treatment of the disease mainly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].